Arcus Biosciences, Inc.RCUSNYSE
Loading
EBITDA Margin Over TimeContracting
Percentile Rank75
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-135.63%
↑ 78% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-623.16%
Historical baseline
PeriodValueYoY Change
2025-135.63%-30.1%
2024-104.26%+58.1%
2023-248.72%-8.0%
2022-230.36%-1595.4%
202115.40%+110.0%
2020-153.85%+71.6%
2019-540.88%+11.7%
2018-612.89%+83.0%
2017-3597.24%-